Morphic Therapeutic Overview

  • Founded

  • 2014

Founded
  • Status

  • Public

  • Employees

  • 102

Employees
  • Stock Symbol

  • MORF

Stock Symbol
  • Share Price

  • $37.27

  • (As of Thursday Closing)

Morphic Therapeutic General Information

Description

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Contact Information

Website
www.morphictx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 35 Gatehouse Drive, A2
  • Waltham, MA 02451
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Morphic Therapeutic Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.27 $37.89 $19.23 - $49.24 $1.5B 39.5M 370K -$1.55

Morphic Therapeutic Financials Summary

In Thousands,
USD 		TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 663,712 663,712 1,323,665 831,101
Revenue 70,808 70,808 19,794 44,945
EBITDA (62,536) (62,536) (94,784) (46,073)
Net Income (59,041) (59,041) (95,542) (44,999)
Total Assets 368,589 368,589 426,290 242,382
Total Debt 3,838 3,838 5,049 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Morphic Therapeutic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Morphic Therapeutic‘s full profile, request access.

Request a free trial

Morphic Therapeutic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeli
Drug Discovery
Waltham, MA
102 As of 2022
00000
00000000000 00000

000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e
0000000000000
San Francisco, CA
000 As of 0000
00000
00000000 00000

000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut la
000000000000000
West Conshohocken, PA
00 As of 0000
000.00
000000 - 000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Morphic Therapeutic Competitors (74)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pliant Therapeutics Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
00 000000000000 Formerly VC-backed Durham, NC 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000000 000000000 Corporation Norcross, GA 00 000000000000
You’re viewing 5 of 74 competitors. Get the full list »

Morphic Therapeutic Executive Team (9)

Name Title Board Seat Contact Info
Praveen Tipirneni MD President, Chief Executive Officer and Board Membe
Bruce Rogers Ph.D Chief Scientific Officer
Marc Schegerin Chief Financial Officer, Finance & Chief Operating Officer, Operations
Robert Farrell Jr. Senior Vice President, Finance & Operations and Treasurer
Blaise Lippa Ph.D Chief Scientific Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Morphic Therapeutic Board Members (16)

Name Representing Role Since
Amir Nashat Ph.D Polaris Partners Board Member 000 0000
Gustav Christensen Morphic Therapeutic Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
Martin Edwards MD Morphic Therapeutic Board Member 000 0000
Nilesh Kumar Ph.D Novo Holdings Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Morphic Therapeutic Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Morphic Therapeutic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Morphic Therapeutic‘s full profile, request access.

Request a free trial

Morphic Therapeutic ESG

Risk Overview

Risk Rating

Updated June, 21, 2022

27.47 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,231

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 899

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 401

Rank

00.00

Percentile

To view Morphic Therapeutic’s complete esg history, request access »